IRCT20090117001556N108RecruitingPhase 3
Tipeptidine as adjuvant therapy in children with ADHD: A double blind and randomised trial
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 6 years to 17 years (—)
- Sex
- All
Inclusion Criteria
- •Diagnosis of ADHD based on DSM-5
- •Age between 6-17 years old
Exclusion Criteria
- •Intellectual disability
- •Presence of any psychiatric disorders except for ODD
- •Receiving any neuroleptic during the last 6 months
- •Weight less than 13.5 kg
- •History of allergy to Tipeptidine or Ritaline
- •Presence of any neurologic disease and any condition requiring surgery
- •Uncontrolled seizures
- •Systolic blood pressure more than 125 mm Hg; resting pulse rate less than 60/minute or more than 115/minute
- •Severe medical disease
- •Receiving any medication or supplement for treatment ADHD
Investigators
Similar Trials
Completed
Phase 1
Tipepidine in children with attention deficit/hyperactivity disorder (AD/HD): a Double-blind, Placebo-controlled TrialAttention deficit/hyperactivity disorder (AD/HD)JPRN-UMIN000015748Department of Psychiatry, Chiba University School of Medicine80
Not yet recruiting
Phase 2
Treatment for autismCTRI/2023/02/050044Impute inc
Active, not recruiting
Not Applicable
Antiangiogenetic therapy for pediatric patients with inoperable benign tumorsEUCTR2008-006992-57-FIsanna kivivuori
Recruiting
Phase 2
Amantadin as adjuvant therapy in the treatment of moderate to severe OCDObsessive-compulsive disorderObsessive- Cumpulsive Disorder.IRCT201705191556N99Tehran University of Medical Sciences50
Completed
Not Applicable
Tipepidine in children with Autism Spectrum Disorder : a 4-week, open-label, preliminary studyAutism Spectrum DisorderJPRN-UMIN000028350Chiba University10